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AMPK: A Target for Drugs and Natural Products With
Effects on Both Diabetes and Cancer
D. Grahame Hardie
The AMP-activated protein kinase (AMPK) is a highly conserved
sensor of cellular energy that appears to have arisen at an early
stage during eukaryotic evolution. In 2001 it was shown to be
activated by metformin, currently the major drug for treatment
for type 2 diabetes. Although the known metabolic effects of
AMPK activation are consistent with the idea that it mediates
some of the therapeutic beneﬁts of metformin, as discussed
below it now appears unlikely that AMPK is the sole target of the
drug. AMPK is also activated by several natural plant products
derived from traditional medicines, and the mechanisms by
which they activate AMPK are discussed. One of these is sa-
licylate, probably the oldest medicinal agent known to human-
kind. The salicylate prodrug salsalate has been shown to improve
metabolic parameters in subjects with insulin resistance and
prediabetes, and whether this might be mediated in part by AMPK
is discussed. Interestingly, there is evidence that both metformin
and aspirin provide some protection against development of
cancer in humans, and whether AMPK might be involved in these
effects is also discussed. Diabetes 62:2164–2172, 2013
AMP-ACTIVATED PROTEIN KINASE: EVOLUTIONARY
BACKGROUND
AMP-activated protein kinase (AMPK) was originally de-
ﬁned as a protein kinase from rat liver that phosphorylated
and inactivated two key enzymes of mammalian fatty acid
and sterol synthesis, i.e., acetyl-CoA carboxylase-1 (ACC1)
and 3-hydroxy-3-methylglutaryl-CoA reductase (1). Its ac-
tivation requires phosphorylation by upstream kinases at
a conserved threonine residue within the kinase domain
(usually termed Thr-172 because of its position in the rat
sequence [2]). Phosphorylation of this site and the major
site phosphorylated on ACC1 (3), detected using phos-
phospeciﬁc antibodies, are now almost universally used as
biomarkers to monitor AMPK activation.
AMPK exists as heterotrimers composed of a catalytic a
subunit and regulatory b and g subunits (4,5). In humans,
each of these occurs as multiple isoforms encoded by
distinct genes (Table 1) such that there are at least twelve
possible heterotrimeric combinations. Genes encoding the
three subunits are also readily recognized in the genomes
of almost all eukaryotes, from simple single-celled proto-
zoa to humans. Based on genetic studies in lower eukar-
yotes, the ancestral role of this conserved pathway appears
to have been in the response to glucose starvation. The
AMPK-signaling pathway represents a mechanism to respond
to ﬂuctuating glucose levels that appears to have evolved
much earlier than the insulin-signaling pathway, which is
only found in multicellular animals. Of particular interest,
in the nematode worm Caenorhabditis elegans AMPK is
required for the extension of life span that is observed in
response to caloric restriction or to mutations that reduce
the function of the insulin-signaling pathway (6,7).
REGULATION OF AMPK BY ADENINE NUCLEOTIDES AND
CALCIUM IONS
The AMPK-g subunits contain three sites that bind adenine
nucleotides and confer the ability of the kinase to act as an
energy sensor (8–10). In cells not subject to energetic
stress, catabolism maintains the ATP:ADP ratio at around
10:1, and this drives the adenylate kinase reaction toward
ADP synthesis (ATP + AMP → 2ADP), so that AMP con-
centrations are very low; the typical ratios of ATP:AMP:
AMP in unstressed cells are around 100:10:1. The g subunit
sites appear to bind AMP, ADP, and ATP with similar af-
ﬁnity, but they preferentially bind free ATP42 rather than
the Mg.ATP22 complex (8). Because around 90% of ATP
(but not ADP or AMP) is present as the magnesium com-
plex, the cellular concentrations of total ADP and free
ATP42 are comparable, allowing these nucleotides to
compete with each other for binding to AMPK. Although
the concentration of AMP is at least 10-fold lower than that
of ADP or free ATP in unstressed cells, it rises markedly as
the ADP:ATP ratio rises during energy stress, due to dis-
placement of the adenylate kinase reaction toward AMP:
2ADP→ ATP + AMP. Under these conditions, AMP should
therefore be able to compete with ATP or ADP at the
AMPK-g subunit binding sites.
Binding of AMP or ADP (but not ATP) to the AMPK-g
subunit causes a conformational change that promotes
phosphorylation of Thr-172 by upstream kinases while
inhibiting dephosphorylation by upstream phosphatases
(8,11,12). Stoichiometric phosphorylation of Thr-172 can
cause .100-fold activation, although Thr-172 may only be
partially phosphorylated in vivo even in cells experiencing
metabolic stress. The effect of increased phosphorylation
is ampliﬁed up to 10-fold further by allosteric activation,
which is caused only by binding of AMP. This tripartite
mechanism (Fig. 1) means that there can be large increases
in AMPK activity in response to small increases in the
AMP:ATP or ADP:ATP ratios.
The major upstream kinase that phosphorylates Thr-172
in mammalian cells was identiﬁed to be a complex con-
taining the tumor suppressor kinase, liver kinase B1
(LKB1) (13–15), introducing a tantalizing link between
AMPK and cancer, which is considered further below.
LKB1 appears to be constitutively active, but its high basal
activity is required for the effect of binding of ADP or AMP
to the g subunit on net Thr-172 phosphorylation to become
evident (13). Thr-172 can also be phosphorylated by the
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PERSPECTIVES IN DIABETES
Ca2+/calmodulin-dependent kinase kinases (CaMKKs), es-
pecially CaMKKb (16–18). This mechanism, which can act
independently of changes in adenine nucleotides, is re-
sponsible for activation of AMPK in response to agonists
that increase intracellular Ca2+ including thrombin in endo-
thelial cells (19), antigen binding to the T-cell receptor (20),
the hunger hormone ghrelin acting on hypothalamic neu-
rons (21), and cannabinoids acting at CB2 receptors (22).
METABOLIC CONSEQUENCES OF AMPK ACTIVATION
By sensing changes in adenine nucleotide ratios, AMPK is
activated by stresses that depress cellular energy status.
These include stresses that inhibit ATP production, such
as hypoxia, hypoglycemia, or addition of mitochondrial
poisons, as well as stresses that accelerate ATP con-
sumption, such as muscle contraction (23). Some of the
major metabolic changes elicited by AMPK activation are
summarized in Table 2; the reader is referred to other
reviews for details (4,5). In many cases, the effects occur
both acutely via direct phosphorylation of metabolic en-
zymes and chronically via phosphorylation of transcription
factors or coactivators that modulate gene expression.
Some of the metabolic effects that ensue following
AMPK activation are particularly relevant to treatment of
type 2 diabetes. By inhibiting fat synthesis and promoting
fat oxidation, and by enhancing mitochondrial biogenesis
and disposal of damaged mitochondria by autophagy (24),
AMPK activation would reverse elevated storage of tri-
glycerides as well as deﬁcits in mitochondrial function,
both of which are associated with insulin resistance
(25,26). Another important effect of AMPK is its ability to
promote glucose uptake in skeletal muscle. This occurs
both acutely via translocation of GLUT4 from intracellular
storage vesicles to the plasma membrane, and in the lon-
ger term by upregulation of GLUT4 expression (27). The
mechanism for the acute effect is similar to that by which
the insulin-signaling pathway promotes glucose uptake, in-
volving phosphorylation of the Rab-GAP protein TBC1D1
by AMPK (28,29). There has been controversy as to whether
AMPK entirely accounts for the increase in glucose up-
take induced by exercise or muscle contraction. Whereas
experiments with mouse knockouts of single catalytic sub-
units (AMPK-a1 or -a2) did not support this view (30),
a study involving a muscle-speciﬁc double knockout of
both AMPK-b subunits, which totally ablates muscle AMPK
activity, did support it (23). The latter study also revealed
that mice lacking AMPK in muscle have reduced mito-
chondrial content and a dramatically reduced capacity for
treadmill running. Human studies suggest that activation of
muscle AMPK during exercise is normal in patients with
type 2 diabetes (31), helping to explain why regular exer-
cise is beneﬁcial for them but also reinforcing the idea that
pharmacological activation of AMPK would be an effective
way to treat the disorder.
ACTIVATION OF AMPK BY METFORMIN AND OTHER
GUANIDINE-BASED DRUGS
Guanidine and its isoprenyl derivative, galegine, are natu-
ral products from the plant Galega ofﬁcinalis, which was
used as a medicinal herb in medieval Europe (32). Met-
formin and phenformin are biguanides, synthetic deriva-
tives of guanidine (Fig. 2). All of these compounds were
tested on animals in the 1920s, but the success of insulin
therapy at that time perhaps caused further studies of
guanidine-based drugs to be put on hold. The biguanides
were ﬁnally introduced for treatment of type 2 diabetes in
the 1950s; phenformin was subsequently withdrawn in the
1970s because of a rare but life-threatening side effect of
lactic acidosis, but metformin is now generally the ﬁrst-
choice drug for treatment of type 2 diabetes.
Although biguanides were already known to reduce
hepatic glucose production and enhance peripheral insulin
sensitivity (32), the ﬁrst clues to their molecular mechanism
TABLE 1
Properties of AMPK subunits. Although the b2, g2, and g3 subunits are most highly expressed in muscle, they are found at low levels in
other tissues
Subunit Gene Yeast ortholog Function Tissue distribution
a1 PRKAA1 Snf1 catalytic subunit ubiquitous
a2 PRKAA2 Snf1 catalytic subunit skeletal/cardiac muscle
b1 PRKAB1 Sip1/Sip2/Gal83 glycogen binding, a/g binding ubiquitous
b2 PRKAB2 Sip1/Sip2/Gal83 glycogen binding, a/g binding skeletal/cardiac muscle
g1 PRKAG1 Snf4 Binding of AMP/ADP/ATP ubiquitous
g2 PRKAG2 Snf4 Binding of AMP/ADP/ATP skeletal/cardiac muscle
g3 PRKAG3 Snf4 Binding of AMP/ADP/ATP skeletal muscle
FIG. 1. Tripartite mechanism by which AMPK is activated by changes in
cellular energy status. Displacement of ATP by ADP and/or AMP at one
or more of the sites on the AMPK-g subunit causes a conformational
change in the heterotrimeric complex that 1) promotes phosphoryla-
tion, and 2) inhibits dephosphorylation of Thr-172, causing a large (up
to 100-fold) increase in kinase activity. Binding of AMP, but not ADP,
causes 3) further activation of the phosphorylated kinase of up to
10-fold. The upstream kinase LKB1 appears to be constitutively active,
and increased Thr-172 phosphorylation in response to energy stress
does not normally occur in tumor cells lacking LKB1. However, AMPK
can also be activated by Thr-172 phosphorylation catalyzed by CaMKKb
via a mechanism that requires an increase in intracellular Ca2+ but can
be independent of changes in AMP and/or ADP.
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came in 2000, when it was shown that they inhibited
Complex I of the mitochondrial respiratory chain
(33,34). Interestingly, both drugs are cations (Fig. 2), so
they accumulate in mitochondria due to the electrical
gradient across the inner membrane (33). Metformin has
poor plasma membrane permeability, but uptake into
many cells (including hepatocytes) is promoted by the
organic cation transporter OCT1, whereas phenformin
uptake is less dependent on this transporter (35). Since
both drugs inhibit mitochondrial ATP synthesis, they
would be expected to cause increases in the ADP:ATP
and AMP:ATP ratios and thus activate AMPK indirectly.
AMPK activation by metformin was indeed demon-
strated in 2001 (36), and this was subsequently also
shown for phenformin (13) and galegine (37). The acti-
vation mechanism requires increases in AMP and/or
ADP, because all three drugs fail to activate AMPK in
cells expressing an AMPK-g subunit with a mutation
(R531G) that renders the complex AMP/ADP insensi-
tive (35).
TABLE 2
Target protein Protein function Effect of phosphorylation Tissue Effect on pathway
acetyl-CoA carboxylase-1 metabolic enzyme ↓ activity ↓ malonyl-CoA all cells? ↓ fatty acid synthesis
acetyl-CoA carboxylase-2 metabolic enzyme ↓ activity ↓ malonyl-CoA muscle, liver ↑ fatty acid oxidation
3-hydroxy-3-methylglutaryl
-CoA reductase
metabolic enzyme ↓ activity liver ↓ sterol synthesis
glycerol phosphate
acyltransferase?
metabolic enzyme ↓ activity adipose tissue ↓ triglyceride synthesis
hormone-sensitive lipase metabolic enzyme antagonizes activation
by PKA
adipose tissue ↓ lipolysis
TBC1D1 Rab-GAP dissociation from
GLUT4 vesicle
skeletal muscle ↑ glucose uptake
glycogen synthase 1 metabolic enzyme ↓ activity in low
[glucose-6-P]
skeletal muscle ↓ glycogen synthesis
glycogen synthase 2 metabolic enzyme ↓ activity in low
[glucose-6-P]
liver ↓ glycogen synthesis
6-phosphofructo-
2-kinase (PKKFB2)
cell signaling ↑ fructose-2,6-
bisphosphate
cardiac muscle ↑ glycolysis
6-phosphofructo-
2-kinase PFKFB3
cell signaling ↑ fructose-2,6-
bisphosphate
macrophages ↑ glycolysis
tuberous sclerosis
complex 2
Rheb-GAP ↑ Rheb-GDP all cells? ↓ mTORC1, protein
synthesis
Raptor mTORC1 subunit ↓ mTORC1 activity all cells? ↓ mTORC1, protein
synthesis
Hepatocyte nuclear
factor-4a
transcription factor ↓ DNA binding,
↑ degradation?
liver, others ↓ transcription
Carbohydrate-responsive
element-binding protein
transcription factor ↓ DNA binding liver, others ↓ transcription of
lipogenic genes
sterol regulatory element-
binding protein 1c
transcription factor ↓ proteolytic cleavage,
activation
liver, others ↓ transcription of
lipogenic genes
transcriptional
intermediary
factor-1A
transcription factor ↓ activity all cells? ↓ ribosomal RNA
synthesis
p300 transcription
coactivator
↓ interaction with
nuclear receptors
most cells? ↓ transcription by
nuclear receptors
CREB-regulated
transcription
coactivator-2
transcription
coactivator
14–3–3 binding/nuclear
exclusion
liver ↓ transcription of
gluconeogenic genes
HDAC4/HDAC5/HDAC7 lysine deacetylases 14–3–3 binding/nuclear
exclusion
liver ↓ transcription of
gluconeogenic genes
Sirtuin 1? lysine deacetylase activation? most cells? ↑ mitochondrial biogenesis
proliferator-activated
receptor
coactivator-1a?
transcription
coactivator
deacetylation/activation most cells? ↑ mitochondrial biogenesis
UNC-51-like kinase 1 protein kinase ↑ activity all cells? ↑ autophagy, mitophagy
cystic ﬁbrosis
transmembrane
regulator
ion channel ↓ channel opening airway, gut ↓ ion transport,
↓ ﬂuid secretion
Kv2.1 ion channel ↑ channel opening neurons ↓ frequency of action
potentials
BKCa (KCa1.1) ion channel ↓ channel opening carotid body ↑ excitability of
type 1 cell
Protein targets for which there is good evidence for regulation by AMPK. A question mark indicates that the protein may not be a direct AMPK
target. The list is not comprehensive; see other reviews (4,5) for full references.
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ARE THE THERAPEUTIC EFFECTS OF METFORMIN
MEDIATED BY AMPK ACTIVATION?
Whether AMPK is the metformin target that entirely
accounts for its therapeutic effects now appears doubtful,
at least when considering its effects on hepatic glucose pro-
duction. A role for AMPK had seemed attractive because
the pharmacological AMPK activator, 5-aminoimidazole-4-
carboxamide riboside (AICAR) (38) downregulated expres-
sion of the gluconeogenic enzymes phosphoenolpyruvate
carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase)
(39), while in mice with a liver-speciﬁc knockout of LKB1
(in which metformin no longer activated AMPK) the hy-
poglycemic effects of metformin were lost (40). However,
in a more recent study in which both AMPK catalytic
subunit isoforms were knocked out in liver, the mice had
normal blood glucose and insulin, while metformin still
reduced the expression of G6Pase and glucose output,
and AICAR reduced the expression of both PEPCK
and G6Pase, in isolated hepatocytes derived from the
mice (41). This study revealed that there must be AMPK-
independent pathways by which not only metformin, but
also AICAR, inhibit expression of gluconeogenic enzymes
and glucose output in the liver.
Evidence in favor of one such AMPK-independent mecha-
nism (Fig. 3) was reported recently (42). The classical acti-
vator of hepatic glucose production is the starvation hormone
glucagon, which increases cyclic AMP and activates cyclic
AMP-dependent protein kinase A (PKA). PKA phosphorylates
the liver (PFKFB1) isoform of 6-phosphofructo-2-kinase/
fructose-2,6-bisphosphatase, leading to a rapid drop in
fructose-2,6-bisphosphate. Since the latter is an activator
of the glycolytic enzyme 6-phosphofructo-1-kinase and
an inhibitor of the gluconeogenic enzyme fructose-
1,6-bisphosphatase, glucagon triggers an acute metabolic
switch from glycolysis to gluconeogenesis. In addition,
PKA enhances expression of gluconeogenic enzymes by
phosphorylation of the transcription factor cyclic AMP
response element-binding protein and other mechanisms.
The increases in cyclic AMP are brought about by acti-
vation of adenylate cyclase by the glucagon receptor,
and adenylate cyclase is directly inhibited by the
metformin-induced increase in AMP, leading to a reduction
in cyclic AMP formation in response to glucagon (42). In-
terestingly, a similar effect was observed with AICAR,
a nucleoside that is taken up into cells and converted to
the equivalent monophosphorylated nucleotide, ZMP (38).
It seems possible that ZMP, like AMP, might inhibit ade-
nylate cyclase, and that this might explain why AICAR was
originally found to inhibit expression of PEPCK and
G6Pase (39).
Interestingly, AMP is also an allosteric inhibitor of
fructose-1,6-bisphosphatase (this too is mimicked by ZMP
[43]) and an activator of PFK1. Because metformin increases
AMP in hepatocytes (42), whereas AICAR increases ZMP
(38), this represents yet another AMPK-independent mech-
anism by which metformin and AICAR might inhibit hepatic
glucose production in vivo.
As well as inhibition of complex I of the respiratory
chain (33,34), it has been proposed that metformin might
act by inhibiting AMP deaminase, an enzyme that degrades
cellular AMP (44). One caveat is that the reported in-
hibition of AMP deaminase in cell-free assays was only
partial even at very high metformin concentrations (10
mmol/L). In any case, the two alternate mechanisms, in-
volving inhibition of the respiratory chain or of AMP de-
aminase, would both be compatible with the results
suggesting that AMPK activation (35) and adenylate cy-
clase inhibition (42) are mediated by increases in AMP.
To conclude this section, it now appears likely that the
effects of metformin to inhibit hepatic glucose production
are not mediated by AMPK but by other mechanisms such
as the inhibition of adenylate cyclase and/or fructose-
1,6-bisphosphatase by AMP. This does not rule out the
possibility that activation of AMPK might account for other
effects of metformin action, such as its ability to enhance
insulin sensitivity. It might, for example, do this by stim-
ulating fat oxidation and inhibiting fat synthesis, thus re-
ducing triglyceride storage in liver and/or muscle.
ACTIVATION OF AMPK BY OTHER NATURAL PRODUCTS
In addition to galegine, a bewildering variety of other
natural products—many derived from plants used as
FIG. 2. Structures of AMPK activators based on guanidine, including
the biguanides metformin and phenformin.
FIG. 3. Schematic diagram of the proposed new mechanism by which
metformin inhibits hepatic gluconeogenesis (42). Up or down arrows
next to a metabolite or enzyme show the direction the concentration or
activity changes in response to metformin. Metformin (whose uptake
into hepatocytes is promoted by the organic cation transporter [OCT1])
accumulates in mitochondria where it inhibits Complex 1 of the re-
spiratory chain, lowering cytoplasmic ATP and increasing ADP and
AMP. AMP activates AMPK but also inhibits adenylate cyclase, re-
ducing effects of glucagon on cAMP and PKA and thus reducing the
ability of PKA to promote gluconeogenesis by phosphorylation of PFK2
and other targets regulating transcription of gluconeogenic genes.
F16BP, fructose-1,6-bisphosphate; F16BPase, fructose-1,6-bisphospha-
tase; F26BP, fructose-2,6-bisphosphate; G6Pase, glucose-6-phospha-
tase; PFK1, 6-phosphofructo-1-kinase; PFK2, 6-phosphofructo-2-kinase/
fructose-2,6-bisphosphatase.
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herbal medicines in Asian countries—have been reported
to activate AMPK. These include resveratrol from red
grapes, quercetin present in many fruits and vegetables,
ginsenoside from Panax ginseng, curcumin from Cur-
cuma longa, berberine from Coptis chinensis (used in the
Chinese herbal medicine Huanglian), epigallocatechin
gallate from green tea, theaﬂavin from black tea (45), and
hispidulin from snow lotus, another plant used in Chinese
herbal medicine (46). Many of these compounds are
claimed to have favorable effects in type 2 diabetes and the
metabolic syndrome. Although many of these compounds
can be classed as polyphenols, their structures are quite
variable (Fig. 4), and a puzzling feature was how such
disparate structures would all be able to activate AMPK.
Based on ﬁndings that berberine inhibited the respiratory
chain (47), whereas resveratrol inhibited the F1 ATP syn-
thase (48), it seemed possible that many of them activated
AMPK indirectly, by inhibiting mitochondrial ATP pro-
duction and thus increasing cellular AMP:ATP and/or
ADP:ATP ratios, in a similar manner to the biguanides.
Supporting this, AMPK activation by resveratrol, berber-
ine, and quercetin was reduced or eliminated in cells
expressing the AMP/ADP-insensitive AMPK mutant (35).
Many of these natural products are secondary metabolites
of plants, and some of them appear to be produced to
defend plants against infection by pathogens or grazing by
herbivorous animals. Production of mitochondrial poisons
may be an effective deterrent, but (observing the aphorism
of Paracelsus that “the dose makes the poison”) at lower
doses these compounds may only cause mild inhibition of
mitochondria yet still have the useful effect of activating
AMPK.
Small-scale pilot trials of some of these compounds have
been conducted in diabetic or obese humans. Two trials of
berberine in subjects newly diagnosed with type 2 diabetes
(49,50) revealed favorable effects on plasma glucose, lip-
ids, and HbA1c, although neither plasma berberine levels
nor AMPK activation were assessed. Two trials of resver-
atrol in obese, nondiabetic males produced conﬂicting
results. The ﬁrst used a randomized, crossover design on
11 subjects given resveratrol (150 mg/day) or placebo for
30 days, and suggested that resveratrol lowered plasma
glucose, insulin, and homeostasis model assessment index,
as well as systolic blood pressure (51). The second used
24 male volunteers randomly assigned to resveratrol
(1.5 g/day) or placebo for 4 weeks and failed to observe
any signiﬁcant effects on plasma glucose, insulin or ho-
meostasis model assessment index, blood pressure, or in-
sulin sensitivity by hyperinsulinemic-euglycemic clamp
(52). Despite the 10-fold higher dose used in the second,
negative study, the levels of plasma resveratrol detected
were similar in both trials (1–2 mmol/L). These are around
50-fold lower than the concentrations usually used to ac-
tivate AMPK in cultured cells (35), yet activation of AMPK
in muscle biopsies was reported in the ﬁrst study, although
not in the second. Thus, it remains unclear whether clini-
cally effective doses of these compounds are sufﬁciently
high to activate AMPK in vivo.
ACTIVATION OF AMPK BY SALICYLATE
Salicylates are natural products produced by many plants
(Fig. 5), and it is now known that they are mediators re-
leased by infected plant tissues, which signal to uninfected
FIG. 4. Structures of plant polyphenols that have been reported to be AMPK activators.
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regions to induce defense responses (53). The use of wil-
low bark (a rich source of salicylates) was described in the
3rd millennium B.C., making it one of the oldest medicines
known to humankind (54). The active component of willow
bark is salicin, a b-glucosyl derivative of salicyl alcohol, the
efﬁcacy of which in rheumatic fever (an inﬂammatory dis-
order now known to be caused by streptococcal infection)
was ﬁrst tested by Thomas MacLagan in the author’s home
town of Dundee in 1876 (55). However, the widespread use
of salicylate-based drugs occurred after the development
of acetyl salicylic acid, a synthetic derivative ﬁrst mar-
keted by Bayer in 1899 under the trade name aspirin (54).
Another form in which salicylate can be taken orally is as
the diester salsalate (Fig. 5), which has been used to treat
rheumatoid arthritis. All salicylates, including salicin,
aspirin, and salsalate, are rapidly converted to salicylate
in vivo, with the plasma half-life of aspirin in humans
being only 10–15 min, while that of the salicylate derived
from it is 3–5 h (56). Salicin, aspirin, and salsalate can
therefore all be regarded as prodrugs for salicylate. The
one clear exception to this concerns the effect of aspirin
to inhibit platelet aggregation, which it achieves by irre-
versible acetylation and inhibition of the cyclooxygenase
COX1, thus reducing synthesis of the prothrombotic
prostanoid, thromboxane A2, for the lifetime of the
platelet. Most other effects of aspirin, including its anti-
inﬂammatory effects, are most likely mediated by salicy-
late.
Salicylate, but not aspirin, was recently found to activate
AMPK in cultured human cells (57). At concentrations
corresponding to plasma concentrations in humans treated
with high doses of aspirin or salsalate, salicylate activated
wild-type AMPK and the AMP/ADP insensitive mutant
equally well, showing that it worked via an AMP/ADP-
independent mechanism. This suggested that it might bind
directly to AMPK, which was subsequently conﬁrmed (57).
Two lines of evidence suggested that salicylate was bind-
ing at the same site as A-769662, a synthetic activator (Fig.
5) derived from a high-throughput screen (58). Thus, ac-
tivation by both agents was 1) speciﬁc for AMPK com-
plexes containing the b1 isoform and 2) abolished by
a point mutation in b1. The ﬁrst ﬁnding also allowed a test,
by using b1-knockout mice, of whether any effects of sa-
licylate in vivo were mediated by AMPK. AMPK is known
to stimulate fat oxidation, which can be monitored in vivo
by measuring the respiratory exchange ratio (RER, ratio
of CO2 exhaled to O2 inhaled). When fasted mice were fed
a carbohydrate meal their RER increased and then de-
clined (as expected) when the food was withdrawn and
they switched back to fat oxidation. However, the drop in
RER was much more precipitous when wild-type mice
were injected with salicylate or A-769662 at the time of
food withdrawal, and this effect was abolished in the b1-
knockout mice (57). These results conﬁrm that the
increases in whole-body fat oxidation induced by either
salicylate or A-769662 were mediated by AMPK activa-
tion.
There have been numerous observational studies sug-
gesting that metabolic parameters improved in diabetic
patients who were taking salicylate-based drugs. To con-
ﬁrm this, Shoelson and colleagues (59) conducted two
randomized controlled trials of salsalate, one for 4 weeks
on obese, nondiabetic subjects and one for 12 weeks on
subjects with impaired fasting glucose or impaired glucose
tolerance (60). These trials showed that oral salsalate de-
creased fasting glucose and insulin C-peptide and in-
creased plasma adiponectin, although in the second study
the treatment did not appear to affect peripheral insulin
sensitivity. It would be tempting to speculate that some of
these effects of salsalate were mediated by activation of
AMPK. However, salicylate treatment for 2 weeks in mice
rendered insulin resistant by feeding of a high-fat diet de-
creased fasting glucose and insulin and improved glucose
tolerance in both the wild-type and b1-knockout mice (57).
This suggests that the effects of salicylate on glucose ho-
meostasis may be AMPK independent.
ROLE OF AMPK IN CANCER
The ﬁndings that the tumor suppressor LKB1 was the
major upstream kinase required for AMPK activation (13–
15) introduced a link between AMPK and cancer. Although
it was subsequently shown that LKB1 also acted upstream
of twelve other AMPK-related kinases (61,62), several
indications suggest that AMPK is likely to exert most, if not
all, of the tumor suppressor functions of LKB1.
1) AMPK activation causes a cell cycle arrest associated
with stabilization of p53 and the cyclin-dependent kinase
inhibitors p21WAF1 and p27CIP1 (63–65).
2) AMPK inhibits the synthesis of most macromolecules
required for cell growth, including lipids, ribosomal
RNA and proteins, the latter in part via inhibition
of the mechanistic target of rapamycin complex-1
(mTORC1) (4,5).
3) By promoting oxidative metabolism (4,5), and inhibit-
ing glycolysis by inhibition of mTORC1 and consequent
downregulation of expression of hypoxia-inducible
factor-1a (66), AMPK promotes a switch away from
the rapid glycolysis observed in most tumor cells (the
Warburg effect) and toward the oxidative metabolism
used by most quiescent cells (67).
Consistent with the idea that AMPK exerts most of the
tumor suppressor effects of LKB1, it has recently been
shown that in a mouse model in which lymphomas are
induced by B-cell–speciﬁc overexpression of Myc, tumor-
free survival was shorter if AMPK-a1 (the only catalytic
subunit expressed in B cells) was knocked out throughout
the body (67).
FIG. 5. Structures of medicinal salicylates and the AMPK activator
A-769662.
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EFFECT OF METFORMIN AND SALICYLATE ON CANCER
IN HUMANS AND IN ANIMAL MODELS
The original ﬁnding of a link between AMPK, LKB1, and
cancer (13) led to a study involving retrospective analysis
of type 2 diabetic patients, which showed that use of
metformin was associated with a signiﬁcantly lower in-
cidence of cancer compared with other medications (68).
This has been reproduced in several subsequent studies,
with a meta-analysis indicating an overall risk reduction of
30%, with speciﬁc risk reductions being found for colon
and liver cancers (69). It should be noted that these ret-
rospective analyses merely report associations and do not
prove a causal link. Some of them have also been criticized
on the basis that they may be subject to time-related biases
(70). However, studies in animal models support the idea
that biguanides and other AMPK activators can be used to
protect against tumor development and even to treat
tumors once they have arisen. For example, metformin
treatment delayed the onset of tumors in mice that were
tumor prone as the result of heterozygous mutations in
PTEN and hypomorphic mutations in LKB1 (71); in-
terestingly, phenformin had an even more pronounced
effect, as did A-769662. Since A-769662 activates AMPK by
a different mechanism from the biguanides (72), this
makes it likely that the delay in tumorigenesis was caused
by AMPK activation rather than AMPK-independent, “off-
target” effects. However, there is also evidence from an-
other animal model that phenformin might be useful for
treating cancer via AMPK-independent effects (73). This
study used mice in which expression of mutant, oncogenic
K-Ras could be combined with loss of either LKB1 or p53
in lung epithelial cells by inhalation of viral vectors
expressing Cre recombinase. In these mice, expression of
mutant K-Ras alone causes some tumors, but combination
with loss of p53 or LKB1 increases the multiplicity of
tumors and metastasis (74). In the new study, treatment of
the mice with oral phenformin from 3 weeks after tumor
initiation prolonged survival of the mice and delayed tu-
mor progression as well as increasing expression of
markers of necrosis and apoptosis in the tumors—but only
in the mice in which LKB1 had been deleted (73). It was
also shown by immunohistochemistry that metformin and
phenformin activated AMPK in lung tumors but, as
expected, only in those that still expressed LKB1. AMPK
activation was greater with phenformin than metformin
(possibly due its greater membrane permeability, as dis-
cussed earlier), which is why phenformin was used in the
analysis of survival. In this study, phenformin is essentially
acting as a cytotoxic agent that causes necrosis or apo-
ptosis of tumor cells because, in the absence of a func-
tional LKB1-AMPK pathway, they are more sensitive to
the ATP-depleting effects of the drug. Although one of
these mouse studies (71) suggests that treatment with
biguanides delays onset of tumors, most likely by AMPK-
dependent effects, the other (73) suggests that phenformin
can be used to treat preexisting tumors that lack a func-
tional AMPK pathway. Thus, while AMPK appears to be
a tumor suppressor that protects against initial tumor de-
velopment, once tumors have arisen it may, paradoxically,
be easier to treat the cancer if the AMPK pathway has been
lost.
Intriguingly, retrospective analysis of randomized con-
trolled trials to study prevention of vascular events has
provided evidence that aspirin also provides protection
against cancer (75,76). Even though there is currently no
evidence that this is caused by AMPK activation, the fact
that aspirin can be regarded as a prodrug for another
AMPK activator, salicylate, suggests that this possibility is
worth considering.
CONCLUSIONS
The metabolic effects of AMPK activation, especially its
ability to cause a metabolic switch from fat synthesis to fat
oxidation and to promote muscle glucose uptake, would
be expected to be beneﬁcial in individuals with insulin
resistance and/or type 2 diabetes. AMPK is activated by
biguanide drugs (metformin and phenformin) and by sa-
licylate, the major breakdown product of aspirin and sal-
salate. Metformin activates AMPK indirectly by inhibiting
mitochondrial function, whereas salicylate binds directly
to AMPK. Metformin is already the drug of ﬁrst choice for
treatment of type 2 diabetes, while salsalate has shown
promise in randomized, controlled trials in subjects with
obesity or prediabetes. However, due to their small size
these drugs will only form low-afﬁnity interactions with
proteins and are likely to bind to multiple targets in vivo.
An increasing number of AMPK-independent effects of
metformin and salicylates are being documented, in-
cluding the effects of metformin on hepatic glucose pro-
duction and of salsalate on glucose homeostasis. None of
this dilutes the attractiveness of AMPK as a target for
novel therapies, particularly because of its ability to cause
a metabolic switch from fat synthesis to fat oxidation. The
Abbott compound A-769662, which appears to bind at the
same site as salicylate (57) and produces favorable
changes in metabolic parameters in ob/ob mice (58), rep-
resents a model for compounds that are direct activators
of AMPK. At the time of writing, nearly 60 patents have
been ﬁled for small-molecule activators of AMPK, and it is
hoped that some of these may enter human clinical trials
soon. It seems likely that by the end of this decade we will
have a much clearer picture of whether drugs that are
more selective activators of AMPK than metformin or sa-
licylate will have a place in the treatment of type 2 diabetes
or cancer.
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